AARTI DRUGS LTD.

Aarti Drugs Ltd has filed a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, detailing changes in shareholding by Dilesh Roadlines Pvt Ltd and other promoters/promoter group entities. The filing indicates a net decrease in the promoter group's shareholding. Specifically, Dilesh Roadlines Private Limited saw a reduction of 125,998 shares, and other promoters collectively sold 1,769,641 shares through market sales, while acquiring 370,156 shares via market purchases. The total promoter group shareholding decreased by 2,265,795 shares, resulting in a revised total holding of 49,681,228 shares, representing 54.03% of the total share capital. The total share capital of the company was adjusted due to a buyback of 665,000 shares.

Aarti Drugs Ltd has announced the closure of its trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from July 1, 2026, until 48 hours after the declaration of the financial results for the quarter ended June 30, 2026. This measure is standard practice to prevent insider trading during the period leading up to and immediately following the announcement of financial performance.

Aarti Drugs Ltd announced its audited financial results for Q4 and FY26. The company's revenue for FY26 stood at ₹2,567.7 crore, a 7% YoY increase. EBITDA was ₹311.6 crore, up 3% YoY, with a margin of 12.1%. PAT reached ₹194.9 crore, a 16% YoY increase, with a margin of 7.6%. Q4 FY26 revenue was ₹721.1 crore, up 6% YoY, while PAT was ₹55.3 crore, down 12% YoY. The Sayakha facility achieved a run-rate of ~1,000 tonnes per month in March 2026.

Aarti Drugs Ltd's board re-appointed M/s GMVP & Associates LLP as Cost Auditor for FY27 and M/s Raman S. Shah & Co. as Internal Auditor for three years starting April 1, 2026. The board also approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Additionally, the Risk Management Committee was reconstituted with the inclusion of Shri Narendra J. Salvi.

Aarti Drugs Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board also approved the re-appointment of M/s GMVP & Associates LLP as Cost Auditor for FY 2026-27 and M/s Raman S. Shah & Co. as Internal Auditor for three years starting April 1, 2026. Additionally, the Risk Management Committee was reconstituted with the inclusion of Shri Narendra J. Salvi as a member.

Aarti Drugs Ltd. announced its financial results for the quarter and year ended March 31, 2026, following a Board of Directors meeting on May 15, 2026. The board approved audited standalone and consolidated financial results, including statements of assets, liabilities, cash flow, and auditor's reports. Additionally, M/s GMVP & Associates LLP was re-appointed as Cost Auditor for FY 2026-27, and M/s Raman S. Shah & Co. was re-appointed as Internal Auditor for three years starting April 1, 2026. The Risk Management Committee was also re-constituted with the inclusion of Shri Narendra J. Salvi.

Aarti Drugs Ltd has scheduled a Board of Directors meeting on May 15, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The trading window remains closed until 48 hours after the declaration of the results.

Aarti Drugs Ltd has initiated the Second 100 Days Campaign - 'Saksham Niveshak' in compliance with the request from the Investor Education and Protection Fund Authority (IEPFA) under the Ministry of Corporate Affairs (MCA). The campaign aims to reach out to shareholders whose dividends remain unpaid or unclaimed, urging them to update their KYC and other related details to claim any unpaid or unclaimed dividends before they get transferred to the Investor Education and Protection Fund (IEPF). Shareholders are required to update their PAN, nomination details, contact information, bank account details, and specimen signature with the Registrar & Share Transfer Agent, MUFG Intime India Private Limited or their Depository Participant. The campaign will run from April 1, 2026, to July 9, 2026.

Aarti Drugs Ltd has announced the closure of its trading window from April 1, 2026, until the expiry of 48 hours after the declaration of Financial Results for the Quarter and Year ended March 31, 2026. This decision is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Aarti Drugs Ltd. has informed about a dispute with the GST Department, which has challenged an order by the Hon'ble High Court of Bombay at the Supreme Court. The dispute is about a Show Cause Notice for an alleged contravention of Rule 96(10) of CGST Rules, proposing to demand IGST of Rs. 230.70 Crores for FY 2017-18 to FY 2021-22. Aarti Drugs had filed a writ petition against the demand and penalty, which was allowed by the High Court. However, the GST Department has now filed a Special Leave Petition before the Supreme Court. The financial impact on the company is currently uncertain, and Aarti Drugs will take appropriate legal steps to defend its position.